Frontlight ResearchEarly access
Active, not recruitingNo phase
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
Key facts
- Who runs it
- Bluejay Diagnostics, Inc.
- Where
- Boston, Gainesville, Nashville, Salt Lake City, and Winston-Salem, United StatesSee the 5 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 700 people, planned
- Started
- 12 Nov 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 1 October 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients (≥22 years of age)
- Diagnosis of sepsis or septic shock based on: the Third International Consensus Definitions (Sepsis-3 criteria) defined as at least one of the following criteria as determined by a treating physician or study physician investigator; Sepsis: suspected or documented infection (i.e., use or intent to use antibiotics as an indicator) and organ dysfunction defined by a Sequential Organ Failure Assessment (SOFA) score ≥2; Septic shock: sepsis requiring vasopressors and serum lactate levels >2 mmol/L (18 mg/dL)
- Admitted or intended to be admitted to the ICU
- At least 3 mL plasma drawn and available for collection (or is anticipated to be able to be drawn and available) within 24 hours of (i.e., up to 24 hours after) the earliest diagnosis of sepsis or septic shock
Who cannot take part
- Prior enrollment into this study
- Prisoners or imprisonment at time of enrollment
- Informed consent as approved by IRB is unable to be obtained
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United States
- University of Florida College of MedicineGainesville, United States
- Vanderbilt University Medical CenterNashville, United States
- Intermountain HealthSalt Lake City, United States
- Wake Forest School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 October 2026